Alnylam’s experimental Alzheimer’s drug shows promising benefits in patients for six months - The Boston Globe
bostonglobe.comSubmitted by thebostonglobe7305 in business
The Cambridge biotech is a pioneer in medicines that rely on RNA interference, a scientific innovation that “silences” disease-causing genes.